KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Short-Term Debt issuances (2016 - 2025)

Historic Short-Term Debt issuances for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $5.0 million.

  • Bristol Myers Squibb's Short-Term Debt issuances changed N/A to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $444.0 million, marking a year-over-year decrease of 8314.35%. This contributed to the annual value of $3.0 billion for FY2024, which is 260000.0% up from last year.
  • According to the latest figures from Q3 2025, Bristol Myers Squibb's Short-Term Debt issuances is $5.0 million.
  • Bristol Myers Squibb's 5-year Short-Term Debt issuances high stood at $3.0 billion for Q1 2024, and its period low was -$353.0 million during Q4 2023.
  • Over the past 5 years, Bristol Myers Squibb's median Short-Term Debt issuances value was $42.0 million (recorded in 2022), while the average stood at $196.8 million.
  • Its Short-Term Debt issuances has fluctuated over the past 5 years, first tumbled by 370000.0% in 2021, then soared by 223359.38% in 2024.
  • Bristol Myers Squibb's Short-Term Debt issuances (Quarter) stood at -$114.0 million in 2021, then skyrocketed by 219.3% to $136.0 million in 2022, then tumbled by 359.56% to -$353.0 million in 2023, then soared by 103.68% to $13.0 million in 2024, then crashed by 61.54% to $5.0 million in 2025.
  • Its Short-Term Debt issuances was $5.0 million in Q3 2025, compared to $58.0 million in Q2 2025 and $368.0 million in Q1 2025.